WealthPKNews

WealthPK News

Image for: From manufacturing to innovation: What China's pharmaceutical shift means for Pakistan

From manufacturing to innovation: What China's pharmaceutical shift means for Pakistan

ISLAMABAD, Oct 23 (INP-Wealth Pakistan) -- China's biotechnology sector is expanding its role in the global pharmaceutical industry, moving beyond the manufacturing of conventional medicines and pharmaceutical ingredients to the development and international licensing of innovative drugs, as growing demand for Chinese-developed therapies creates new opportunities for international research and commercial partnerships.

WealthPK Reports

WealthPK Reports

Data News

Image for: HBL declares H1’26 profit before tax of Rs 73.1 billion, reflecting continued client focus and disciplined execution of strategy

HBL declares H1’26 profit before tax of Rs 73.1 billion, reflecting continued client focus and disciplined execution of strategy

HBL today declared a consolidated profit before tax of Rs 73.1 billion, and a profit after tax of Rs 34.5 billion for the half year ended June 30, 2026. EPS for H1’26 increased to Rs 23.51. Along with the results, the Bank declared an interim cash dividend for the second quarter ended June 30, 2026, at Rs 6.0 per share. This is in addition to the interim cash dividend already paid at Rs 6.0 per share.

HBL